Discontinue if paradoxical bronchospasm w/ immediate increase in wheezing after dosing occurs. Not to be used for acute symptom relief ie, as rescue therapy for acute episodes of bronchospasm. CV effects eg, cardiac arrhythmias (atrial fibrillation & tachycardia). Possible systemic effects include hypothalamic‐pituitary‐adrenal suppression, decreased bone mineral density, cataract, glaucoma & central serous chorioretinopathy. Possible pneumonia development in COPD patients. Patients w/ narrow-angle glaucoma or urinary retention; history of prior pneumonia, low BMI & severe COPD; stomach or intestinal ulcers, DM, viral infections; smokers. Monitor patients w/ moderate to severe hepatic impairment for systemic corticosteroid-related adverse reactions. Severe hepatic impairment. Pregnancy & lactation. Childn & adolescents <18 yr.
Weakened or antagonised effect of β2-adrenergic agonists eg, vilanterol w/ β-adrenergic blockers. Increased systemic exposure w/ strong CYP3A4 inhibitors eg, ketoconazole, ritonavir. Potentiated effect of adrenergic agonists on CV system w/ MAOIs, TCAs or drugs prolonging QTc interval. Not recommended in co-administration w/ other long-acting muscarinic antagonists or β2-adrenergic agonists. Potentiated possible hypokalaemic effect of β2-adrenergic agonists w/ methylxanthine derivatives, steroids or non-K-sparing diuretics.
R03AL08 - vilanterol, umeclidinium bromide and fluticasone furoate ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Sign Out
